Phio Pharmaceuticals Corp. (PHIO) · Oct 13, 2026 · Other events

Phio Pharmaceuticals clears PH-762 manufacturing hurdle for Phase 2b

Commercial-scale batch released — First commercial-scale cGMP batch released for planned Q1 2027 Phase 2b

Phio Pharmaceuticals’ manufacturing update removes a key PH-762 supply risk, but the Phase 2b path still depends on final drug product and regulatory execution.

Phio is a clinical-stage biotech moving PH-762 from a completed Phase 1b study toward a proposed Phase 2b program in cutaneous squamous cell carcinoma, after reporting encouraging response and safety data; its cash runway was previously projected into the first half of 2027.

The filing removes a real execution hurdle. Phio released its first commercial-scale cGMP batch of PH-762 drug substance, with the batch made under specified quality requirements and cGMP processes. 〔0〕 〔1〕 That matters because the company had already disclosed manufacturing development work and a planned Phase 2b path; this update shows the supply chain has produced validated material rather than merely having a manufacturing plan.

This advances readiness, not clinical or regulatory certainty. The drug substance still has to pass through final drug-product completion, and the Phase 2b start remains a company expectation rather than a confirmed trial launch. The filing therefore de-risks manufacturing and timing execution, but does not add new efficacy data, FDA authorization, or evidence that the Phase 2b design has been accepted.

Bottom line: This is a meaningful operational step beyond the prior roadmap, because PH-762 has now reached commercial-scale drug-substance production. It strengthens the path to Phase 2b, while leaving final product completion and regulatory execution as the remaining gates.ಎ

What to watch next

Phase 2b trial initiation, first quarter 2027

Original filing on SEC EDGAR

More Phio Pharmaceuticals Corp. news

Phio Pharmaceuticals clears PH-762 manufacturing hurdle for Phase 2b | PHIO Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.